Latest News and Press Releases

Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected to extend cash runway through initial...

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

FORT WORTH, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

FORT WORTH, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

Voriconazole Inhalation Powder (TFF VORI) is an investigational, inhaled formulation of voriconazole developed using TFF Pharmaceuticals Thin Film Freezing technology that is currently being evaluated...

National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered...

FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences...

FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...